ARTICLE

Volume 3,Issue 7

Cite this article
1
Download
17
Citations
80
Views
20 May 2025

冠心病患者肠道菌的通路协同分析

兴艺 郑1 雨菲 王2 睿 张3 新钰 王2 跃娟 刘1
Show Less
1 哈尔滨医科大学大庆校区 医学信息学系, 中国
2 哈尔滨医科大学大庆校区 药学院, 中国
3 哈尔滨医科大学大庆校区 临床医学院, 中国
MRP 2025 , 3(5), 12–14; https://doi.org/10.61369/MRP.2025050008
© 2025 by the Author. Licensee Art and Design, USA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

冠心病(CHD)的发生与肠道菌群紊乱密切相关,但其协同作用机制尚未完全阐明。本研究通过整合多组学数据,筛选冠心病患者肠道菌群特征性物种及代谢通路,探讨菌群间协同作用对宿主代谢的影响。利用TOPSIS算法筛选出30个与CHD显著相关的核心菌群,并通过IGM平台和KEGG通路分析揭示其参与的脂代谢、炎症反应等关键通路。UniProt功能注释进一步表明,目标菌群代谢物(如短链脂肪酸、氧化三甲胺)可能通过调控宿主免疫及内皮功能影响CHD进程。本研究为揭示肠道菌群协同机制提供了新的理论依据,并为CHD的精准干预策略奠定基础。

Keywords
冠心病
肠道菌群
TOPSIS分析
KEGG通路
代谢标志物
协同分析
References

[1]Kazemian N, Mahmoudi M, Halperin F,et al. Gut microbiota and cardiovascular disease: opportunities and challenges. Microbiome. 2020 Mar14;8(1):36.
[2]Katsimichas T, Theofilis P, Tsioufis K,et al. Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives. Metabolites. 2023 Feb9;13(2):256.
[3]Wang Z, Zhao Y. Gut microbiota derived metabolites in cardiovascular health and disease. Protein Cell. 2018 May;9(5):416-431.
[4]Andrade C. The <i>P</i> Value and Statistical Significance:Misunderstandings, Explanations, Challenges, and Alternatives. Indian J Psychol Med. 2019 May-
Jun;41(3):210-215. doi: 10.4103/IJPSYM.IJPSYM_193_19.
[5]Jiang XC, Liu J. Sphingolipid metabolism and atherosclerosis. Handb ExpPharmacol. 2013;(216):133-46.
[6]Won JS, Singh AK, Singh I. Lactosylceramide: a lipid second messenger inneuroinflammatory disease. J Neurochem. 2007 Nov;103 Suppl 1:180-91.
[7]You X, Gao B. Association between Intestinal Flora Metabolites and Coronary Artery Vulnerable Plaque Characteristics in Coronary Heart Disease. Br J Hosp Med (Lond).
2025 Mar 26;86(3):1-13.
[8]Manzo OL, Nour J, Sasset L, et al. Rewiring Endothelial Sphingolipid Metabolism to Favor S1P Over Ceramide Protects From Coronary Atherosclerosis. Circ Res. 2024 Apr
12;134(8):990-1005.
[9]Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol. 2021 Oct;18(10):701-711.
[10]Zhang R ,Ji X ,Tang Y , et al.Chitooligosaccharides Ameliorate Glomerular Mesangial Proliferation and Inflammation in IgA Nephropathy by Blocking S1PR1/S1PR3 Pathway[
J/OL].Food Science and Human.
[11] 廖晶, 周佳, 李龙.S1P在特发性肺纤维化中的研究进展[J].临床肺科杂志,2025,30(04):606-611.
[12]Wang Z, Zhao Y. Gut microbiota derived metabolites in cardiovascular health and disease. Protein Cell. 2018 May;9(5):416-431. doi:10.1007/s13238-018-0549-0. Epub 2018 May 3.
[13] 王琳. 稳定型冠心病患者肠道菌群变化特点的研究[D]. 西安医学院,2020.

Share
Back to top